MML Investors Services LLC Sells 9,319 Shares of IQVIA Holdings Inc. $IQV

MML Investors Services LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 162,356 shares of the medical research company’s stock after selling 9,319 shares during the period. MML Investors Services LLC owned about 0.10% of IQVIA worth $36,597,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Measured Wealth Private Client Group LLC bought a new stake in IQVIA during the 3rd quarter valued at $30,000. Finally, Activest Wealth Management raised its holdings in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent analyst reports. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Truist Financial lowered their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Finally, Morgan Stanley set a $225.00 price target on shares of IQVIA in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Down 1.9%

Shares of IQVIA stock opened at $178.07 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company’s fifty day simple moving average is $173.65 and its two-hundred day simple moving average is $193.06. The company has a market cap of $29.72 billion, a P/E ratio of 22.07, a PEG ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the business posted $2.70 EPS. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.